| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Deferoxamine is an novel iron chelator that is able to bind to free iron in a stable complex, it is also a bacterial siderophore produced by the Actinobacteria Streptomyces pilosus. It has medical applications as a chelating agent used to remove excess iron from the body. The mesylate salt of DFO-B is commercially available. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. Deferoxamine acts by binding free iron in the bloodstream and enhancing its elimination in the urine.
| ln Vitro |
In MEF cells, deferoxamine mesylate (1 mM; 16 hours or 4 weeks) lowers ROS and enhances HIF-1α function in hypoxic and hypertensive environments [1]. Deferoxamine mesylate (5, 10, 25, 50, 100 μM; 7 or 9 days) suppresses the expression of tumor-associated MSCs and bone marrow MSCs proliferate and produce an increase in p-Akt/total Akt/PKB levels. Deferoxamine mesylate (100 μM; 24 hours) enhances InsR expression and activity. In depleted stem cells, deferoxamine mesylate (5, 10, 25, 50, 100 μM; 7 days) causes inflammation [3]. Cell Expression of Damage Proteins in Mesenchymal Stem Cells[3] Deferoxamine mesylate (10 μM; 3 days) influences deferoxamine mesylate (100 μM; 24 h) in SH-SY5Y cells, producing autophagy changes mediated by HIF-1α levels.
|
|---|---|
| ln Vivo |
In elderly or diabetic people, deferoxamine mesylate (6.57 μg/mouse; intravenous drip; once daily for 21 days) accelerates wound healing and increases new blood vessels [1]. Deferoxamine mesylate (200 mg/kg; intraperitoneal; once day for two weeks) elevates trophic, glucose InsR expression, and in vivo signaling prevalence in addition to stabilizing HIF-1α [2].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: MEFs Cell Tested Concentrations: 1 mM Incubation Duration: 16 hrs (hours) (hypoxic conditions); 4 weeks (hyperglycemic conditions) Experimental Results: Under hypoxic and high glucose conditions, the increase in ROS levels associated with hyperglycemia was Dramatically attenuated. Normoxia HIF transactivation is Dramatically increased in MEFs under both high- and normoglycemic conditions. Western Blot Analysis[2] Cell Types: HepG2 Cell Tested Concentrations: 100 µM Incubation Duration: 24 hrs (hours) Experimental Results: Twofold increase in InsR mRNA levels in cells. At the half-maximal concentration of 1.1 nM, InsR binding activity increased twofold. Cell proliferation assay[3] Cell Types: TAMSC and BMMSC (all isolated from male C57BL/6J mice (8 weeks old; EG-7 induced tumor model)) Tested Concentrations: 5, 10, 25, 50, 100 µM Incubation Duration: Day 7 (TAMSC); Day 9 (BMMSCs) Experimental Results: When exposed to 50 and 100 μM doses, the growth of TAMSCs and BMMSCs wa |
| Animal Protocol |
Animal/Disease Models: Aged (21 months old) and diabetic (12 weeks old) C57BL/6J mice (excision wound model) [1].
Doses: 6.57 µg/each (10 uL, 1 mM) Route of Administration: Infusion; one time/day for 21 days. Experimental Results: Demonstrated Dramatically accelerated healing and increased neovascularization in aged and diabetic mouse models. Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat (180-200 g) [2]. Doses: 200 mg/kg Route of Administration: intraperitoneal (ip) injection; one time/day for 2 weeks. Experimental Results: The liver HIF-1α protein level was Dramatically increased, and the InsR protein level, Akt/PKB and activated Akt/PKB in the liver were Dramatically increased. |
| References |
[1]. Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139(3):695e-706e.
[2]. Dongiovanni P, et al. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008 Mar;172(3):738-47. [3]. Wang G, et al. In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow. Environ Toxicol Pharmacol. 2017 Jan;49:58-64. [4]. Wu Y, et al. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010 Oct;57(3):198-205. [5]. Bellotti D, et al. Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. Molecules. 2021 May 28;26(11):3255. |
| Molecular Formula |
C26H52N6O11S
|
|---|---|
| Molecular Weight |
656.79
|
| CAS # |
138-14-7
|
| Related CAS # |
Deferoxamine;70-51-9
|
| SMILES |
O=C(N(CCCCCN)O)CCC(NCCCCCN(C(CCC(NCCCCCN(C(C)=O)O)=O)=O)O)=O.CS(=O)(O)=O
|
| InChi Key |
IDDIJAWJANBQLJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-261-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)1H3,(H,2,3,4)
|
| Chemical Name |
N4-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxy-butanediamide,
monomethanesulfonate
|
| Synonyms |
Deferoxaminum Deferoxamin Desferin
Deferrioxamine B DFOA, Desferal, Ba 33112 DFOM DFX NSC 644468
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~380.64 mM)
DMSO : ~100 mg/mL (~152.26 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5.56 mg/mL (8.47 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5226 mL | 7.6128 mL | 15.2256 mL | |
| 5 mM | 0.3045 mL | 1.5226 mL | 3.0451 mL | |
| 10 mM | 0.1523 mL | 0.7613 mL | 1.5226 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA